1. Introduction {#sec1-cancers-10-00027}
===============

Head and neck squamous cell carcinoma (HNSCC) is a disease with a high incidence and an anatomically heterogeneous group of solid tumors affecting mainly the oral cavity, pharynx (naso-, oro-, and hypopharynx) and larynx \[[@B1-cancers-10-00027]\]. Major risk factors for HNSCC include sex, tobacco smoking, alcohol consumption, and an oncovirus infection \[[@B2-cancers-10-00027]\]. In recent decades, the overall incidence of HNSCC has been declining in the developed world due to a reduction in the consumption of tobacco. However, there is a concomitant increase in the incidence of oropharyngeal cancer as a result of human papillomavirus (HPV) infection \[[@B3-cancers-10-00027],[@B4-cancers-10-00027]\]. Additionally, HPV-related tumors more frequently arise in the oropharynx, whereas HPV-negative tumors are more common in the hypopharynx, larynx, or oral cavity \[[@B5-cancers-10-00027]\].

Interestingly, HPV-related HNSCC is a distinct clinical entity, with a significantly improved treatment response and survival rates in comparison to HPV-negative HNSCC \[[@B6-cancers-10-00027]\]. In general, the 5-year overall survival for HPV-negative HNSCC is around 50%, while that for HPV-related HNSCC patients is around 80% \[[@B7-cancers-10-00027],[@B8-cancers-10-00027]\]. The biological mechanisms underlying the different outcomes in HPV-negative versus HPV-related HNSCC remain poorly understood. It is, therefore, critically important to find biomarkers for HPV-negative HNSCC in order to facilitate patient stratification and improve treatment outcomes.

Aberrant promoter methylation is considered a major mechanism underlying the inactivation of tumor-related genes (TRGs). Notably, the methylation profile of gene promoters is different for each type of tumor, allowing the identification of patterns of tumor-specific hypermethylation \[[@B9-cancers-10-00027]\]. Global DNA methylation profiling has revealed that HPV-related HNSCC is a unique molecular entity that exhibits hypermethylation compared to HPV-negative tumors \[[@B10-cancers-10-00027],[@B11-cancers-10-00027],[@B12-cancers-10-00027]\]. It is important to keep in mind that the molecular spectrum of HNSCC reflects strong influences of what appear to be significantly different tumor microenvironments \[[@B12-cancers-10-00027]\]. Therefore, the development of an integrated analysis method, applicable to various tumor types, is necessary to understand the correlation between a primary tumor site and tumor-specific characteristics.

The aim of this study was to determine the methylation status of TRGs to evaluate their clinical significance as prognostic biomarkers for survival and risk for recurrence in HPV-negative HNSCC. In an attempt to determine if these DNA methylation events are specific to anatomical sites, we have evaluated and compared the methylation changes originating in different anatomical sites (hypopharynx, larynx, and oral cavity). This site-specific analysis may serve as a valuable resource to determine biomarkers for prediction of clinical outcomes in patients with HPV-negative HNSCC.

2. Results {#sec2-cancers-10-00027}
==========

2.1. Characteristics of Patients {#sec2dot1-cancers-10-00027}
--------------------------------

The clinicopathological data of the 178 HNSCC patients included in the study are summarized in [Table 1](#cancers-10-00027-t001){ref-type="table"}. The study population comprised of 153 (86%) men and 25 (14%) women with an age range of 32--92 years (mean ± SD.: 65.8 ± 11.2 years). While 61 (34%) patients had hypopharyngeal cancer, 49 (28%) had laryngeal cancer, and 68 (38%) had oral cavity cancer in the head and neck region. The rates of smoking and alcohol drinking were both 75%. Most patients (75%) had an advanced stage disease (III/IV) at diagnosis, and positive recurrence events were noted in 67 cases (38%) ([Table 1](#cancers-10-00027-t001){ref-type="table"}).

2.2. Analysis of Methylation Status of Tumor-Related Genes {#sec2dot2-cancers-10-00027}
----------------------------------------------------------

The frequencies of the promoter hypermethylation of the 30 genes are shown in [Figure 1](#cancers-10-00027-f001){ref-type="fig"}. The mean number of methylated genes in the full panel was 14.3 (range, 2--25). The overall frequencies of promoter methylation indicated that five genes (*SST*, *SSTR1*, *HCRTR2*, *NPFFR1*, and *NPFFR2*) were frequently methylated (greater than 70%), while three genes (*GAL*, *NPY*, and *CDH13*) were less frequently methylated (less than 30%). We also performed detailed stratified analyses to determine the distributions of methylation status based on the original cancer site. This analysis revealed that methylation frequencies of *SST*, *SSTR1*, *HCRTR2*, *NPFFR1*, and *NPFFR2* genes were greater than 70% in the hypopharynx, larynx, and oral cavity. Notably, the less frequently methylated genes (less than 30%) were as follows: *CDH13*, *p16*, *MGMT*, *GAL*, *NPY*, *GALR2*, and *VEGFR3* for hypopharyngeal cancers; *CDH13*, *p16*, *RASSF1A*, *GAL*, *NPY*, and *NPY1R* for laryngeal cancers; and *CDH13* and *GAL* for oral cavity cancers ([Figure 1](#cancers-10-00027-f001){ref-type="fig"}). The methylation status of the 30 tumor-related gene promoters was determined in an additional 516 HNSCC samples and 50 normal samples. The average β values for *p16*, *COAL1A2*, *DAPK*, *CCBE1*, *DCC*, *SALL3*, *NPY*, *TAC1*, *SST*, *GALR1*, *GALR2*, *NPY1R*, *NPY2R*, *NPY4R*, *NPY5R*, *TACR1*, *HCRTR1*, *HCRTR2*, *SSTR1*, *NPDDR1*, *NPFFR2*, *VEGFR1*, *VEGFR2*, and *VEGFR3* methylation were significantly higher in the HNSCC samples than in the normal samples (*p* \< 0.05). Methylation of the *CDH13*, *MGMT*, *CDH1*, *RASSF1A*, *GAL*, and *HCRT* promoters was not associated between HNSCC and normal control group. ([Figure S1](#app1-cancers-10-00027){ref-type="app"}).

2.3. Correlation Between Gene Methylation and the Original Tumor Site {#sec2dot3-cancers-10-00027}
---------------------------------------------------------------------

[Table 2](#cancers-10-00027-t002){ref-type="table"} shows the correlation between the methylation status of TRGs and the original tumor site. Methylation of the *p16* gene had a significantly higher frequency in oral cavity cancers when compared to hypopharyngeal and laryngeal cancers (*p* \< 0.001 and *p* = 0.006, respectively). Methylation of the *GAL* gene had a significantly lower frequency in hypopharyngeal cancers when compared to laryngeal cancers and oral cavity cancers (*p* = 0.035 and *p* = 0.007, respectively). Patients with oral cavity cancers showed a significantly higher *NPY* methylation in comparison to patients with hypopharyngeal cancers (*p* = 0.003). We also found significantly lower methylation of the *HCRT* gene in laryngeal cancers compared to hypopharyngeal cancers and oral cavity cancers (*p* = 0.016 and *p* = 0.025, respectively). The *GALR2* gene methylation was significantly lower in hypopharyngeal cancers compared to laryngeal cancers and oral cavity cancers (*p* = 0.026 and *p* \< 0.001, respectively) ([Table 2](#cancers-10-00027-t002){ref-type="table"}).

2.4. Correlation Between TRG Methylation and Clinicopathological Assessment {#sec2dot4-cancers-10-00027}
---------------------------------------------------------------------------

Methylation index (MI) was defined as the ratio between the number of methylated genes and the total number of tested genes in each sample. The mean differences in MI according to the age of onset, sex, alcohol consumption, smoking habit, tumor size, lymph node status, clinical stage, and recurrence are illustrated in [Figure 2](#cancers-10-00027-f002){ref-type="fig"}. Continuous marker methylation analyses showed no association between the MI for the 30 TRGs and any clinical parameters in the full panel of 178 patients ([Figure 2](#cancers-10-00027-f002){ref-type="fig"}A) or just in patients with hypopharyngeal ([Figure 2](#cancers-10-00027-f002){ref-type="fig"}B) and laryngeal cancers ([Figure 2](#cancers-10-00027-f002){ref-type="fig"}C). Notably, we found that the MI was significantly higher in the recurrence-positive cases (16.7 ± 5.1) compared to the recurrence-negative cases (13.5 ± 5.2; *p* = 0.017) of oral cancers ([Figure 2](#cancers-10-00027-f002){ref-type="fig"}D).

2.5. Associations Between TRGs Methylation and Survival {#sec2dot5-cancers-10-00027}
-------------------------------------------------------

The association between methylation and risk of recurrence was estimated via a multivariate analysis using a Cox proportional hazards model adjusted for age (≥70 years vs. \<70 years), sex, alcohol consumption, smoking status, and clinical stage. In patients with hypopharyngeal cancers, methylation of *COL1A2* and *VEGFR1* promoters correlated positively with recurrence (odds ratio (OR) = 3.19, 95% CI: 1.33--7.66, *p* = 0.009 and OR = 3.07, 95% CI: 1.25--7.49, *p* = 0.014, respectively) ([Figure 3](#cancers-10-00027-f003){ref-type="fig"}A). In patients with laryngeal cancers, methylation of *p16* and *COL1A2* promoters were associated with poor survival (OR = 4.55, 95% CI: 1.36--15.2, *p* = 0.013 and OR = 3.12, 95% CI: 1.08--8.99, *p* = 0.035, respectively). The opposing influences of promoter methylation of *CCBE1* and *SST* showed association with the OR for recurrence (OR = 0.21, 95% CI: 0.07--0.66, *p* = 0.007 and OR = 0.29, 95% CI: 0.09--0.90, *p* = 0.033, respectively) ([Figure 3](#cancers-10-00027-f003){ref-type="fig"}B). In patients with oral cavity cancers, hypermethylation of *DAPK*, *TAC1*, *GALR1*, *NPY1R*, *SSTR1*, and *VEGFR3* was associated with significantly reduced survival, with hazard ratios of 2.93 (95% CI: 1.17--7.35), 4.29 (95% CI: 1.54--11.9), 2.44 (95% CI: 1.00--5.96), 2.37 (95% CI: 1.05--5.34), 5.38 (95% CI: 1.19--24.3), and 2.55 (95% CI: 1.12--5.78), respectively ([Figure 3](#cancers-10-00027-f003){ref-type="fig"}C).

3. Discussion {#sec3-cancers-10-00027}
=============

This study reports a real-time PCR analysis of DNA methylation profiles obtained from the genomic DNA of 178 HNSCC tissues derived from cancers originating in three anatomical sites. Overall, we found that aberrant promoter methylation patterns of specific TRGs are indicators of an increased risk of recurrence. Therefore, the development of an integrated analysis method, applicable to various tumor types, is necessary to determine the correlation between the primary tumor site and the tumor-specific characteristics.

Interestingly, we found a strong association between the methylation levels of *COL1A2* and disease-free survival (DFS) in hypopharyngeal and laryngeal cancers, but not in oral cavity cancers. *COL1A2* is a fibrillar collagen found in most connective tissues and is the main component of the organic part of bones \[[@B13-cancers-10-00027]\]. Hypermethylation of *COL1A2* has been described in breast carcinomas \[[@B14-cancers-10-00027]\], melanomas \[[@B15-cancers-10-00027]\], and medulloblastomas \[[@B16-cancers-10-00027],[@B17-cancers-10-00027]\]. The *COL1A2* methylation status may, therefore, serve as an important site-specific biomarker for the prediction of clinical outcomes in patients with hypopharyngeal and laryngeal cancers.

In laryngeal cancers, the OR for recurrence is higher when the *p16* promoter is methylated versus unmethylated. On the other hand, there is no association between *p16* methylation and prognosis in hypopharyngeal and oral cavity cancers. The *p16* promoter hypermethylation is a widespread epigenetic alteration, which is known to play a significant role in activating *p16* in many tumor types \[[@B9-cancers-10-00027],[@B18-cancers-10-00027],[@B19-cancers-10-00027]\]. Although our results were consistent with these reports, there was a discrepancy in the anatomical subtype. The association of HPV-positive oropharyngeal cancer with methylation levels of the *p16* promoter regions is still controversial. Nakagawa et al. have reported a very low frequency of *p16* promoter region hypermethylation by pyrosequencing. Non-small cell lung cancer patients with hypermethylation of the *p16* promoter are at a moderate risk of recurrence and death in all populations considered \[[@B20-cancers-10-00027],[@B21-cancers-10-00027]\]. Our data, plus that of others, therefore suggest that *p16* methylation affects tumor behavior and clinical outcomes through interaction with tobacco exposure.

In patients with oral cavity cancers methylation of some genes, including *DAPK*, *NPY*, *TAC1*, *GALR1*, *NPY1R*, *NPY2R*, *SSTR1*, and *VEGFR3* correlated with poor survival. We have carefully reviewed the literature on the association between methylation of TRGs and survival in patients with HNSCC ([Table 3](#cancers-10-00027-t003){ref-type="table"}) \[[@B22-cancers-10-00027],[@B23-cancers-10-00027],[@B24-cancers-10-00027],[@B25-cancers-10-00027],[@B26-cancers-10-00027],[@B27-cancers-10-00027],[@B28-cancers-10-00027],[@B29-cancers-10-00027],[@B30-cancers-10-00027],[@B31-cancers-10-00027],[@B32-cancers-10-00027],[@B33-cancers-10-00027],[@B34-cancers-10-00027],[@B35-cancers-10-00027],[@B36-cancers-10-00027]\]. Oral cavity cancer is a multifactorial disease in which chronic alcohol and tobacco use constitute two major risk factors, while chronic inflammation, viral infections, betel quid/areca-nut chewing, and genetic predisposition are supplementary factors that contribute towards its pathogenesis \[[@B37-cancers-10-00027]\]. Chronic inflammation of the oral mucosa is another risk factor that can potentially modify the methylation status of various genes in oral cavity cancer tumors \[[@B38-cancers-10-00027]\]. The occurrence of multiple cytosine-phosphate-guanine (CpG) methylation sites in a panel of TRGs in oral cavity cancer was highly associated with the stage of cancer progression \[[@B32-cancers-10-00027]\]. Recently, it is reported that saliva-derived DNA is a surrogate noninvasive biomarker panel to discriminate healthy controls from patients with HNSCC \[[@B39-cancers-10-00027],[@B40-cancers-10-00027],[@B41-cancers-10-00027]\]. Therefore, epigenetic alterations may contribute to the etiology of oral carcinogenesis by transcriptional silencing.

Generally, HPV-negative HNSCCs were more broadly distributed among different anatomical sites, compared to the HPV-related tumors, and commonly occurred in the context of heavy alcohol or tobacco use \[[@B42-cancers-10-00027]\]. Despite continuous efforts to identify molecular markers for early detection, and to develop effective treatments, the survival and prognosis of HNSCC patients remain poor \[[@B43-cancers-10-00027]\]. Locoregional recurrence and metastasis are the limiting factors for successful treatments \[[@B43-cancers-10-00027]\]. Profiling DNA methylation is a widely applied tool to identify subtypes of cancers and to predict therapy outcomes \[[@B44-cancers-10-00027]\]. Several studies have been carried out to explore the association between changes in DNA methylation and survival of patients with hypopharynx, larynx, and oral cavity cancers \[[@B22-cancers-10-00027],[@B23-cancers-10-00027],[@B24-cancers-10-00027],[@B25-cancers-10-00027],[@B26-cancers-10-00027],[@B27-cancers-10-00027],[@B28-cancers-10-00027],[@B29-cancers-10-00027],[@B30-cancers-10-00027],[@B31-cancers-10-00027],[@B32-cancers-10-00027],[@B33-cancers-10-00027],[@B34-cancers-10-00027],[@B35-cancers-10-00027],[@B36-cancers-10-00027]\]. As we proceed towards personalized and precision medicine, it is important to remember that, though the genetic material is identical in every cell, epigenetics introduces high variability within different tissues and cell types and is affected by environmental factors \[[@B45-cancers-10-00027],[@B46-cancers-10-00027]\]. Our findings, therefore, suggest that such methylation markers could be used in clinical practice to identify patients who may benefit from adjuvant therapy after an initial surgical treatment. Furthermore, HPV-negative HNSCCs originating in different anatomical sites showed some site-specific DNA methylation events.

4. Materials and Methods {#sec4-cancers-10-00027}
========================

4.1. Tumor Samples {#sec4dot1-cancers-10-00027}
------------------

Primary HNSCC samples (*n* = 178) were obtained from patients during surgery at the Department of Otolaryngology, Hamamatsu University School of Medicine (Hamamatsu, Shizuoka, Japan). All patients provided written informed consent, and the study protocol was approved by the Institutional Review Board of the Hamamatsu University School of Medicine. Clinical information, including age, sex, tumor site, smoking habit, alcohol consumption, tumor size, lymph node status, stage grouping, and recurrence events were all obtained from the patients' clinical records.

4.2. Bisulfite Treatment and Quantitative Methylation-Specific PCR (Q-MSP) Analysis {#sec4dot2-cancers-10-00027}
-----------------------------------------------------------------------------------

Genomic DNA was extracted from tumor and normal mucosal tissues using the QIAamp DNA MiniKit (Qiagen, Courtaboeuf, France). DNA was subjected to bisulfite treatment, as described previously \[[@B47-cancers-10-00027]\]. The bisulfite-modified DNA was used as a template for fluorescence-based real-time PCR \[[@B48-cancers-10-00027]\]. The amplifications were performed using a TaKaRa Thermal CyclerDice™ Real Time System TP800 (TaKaRa, Tokyo, Japan). The Q-MSP primers for methylated DNA were Q-MSP-*ACTB*-F (5′-TGGTGATGGAGGAGGTTTAGAAGT-3′) and Q-MSP-*ACTB*-R (5′-AACCAATAAAACCTACTCCTCCCTTAA-3′). A standard curve was generated using serial dilutions of universally methylated DNAs (EpiScope™ Methylated HCT116 gDNA; TaKaRa, Tokyo, Japan). We determined the specificity of these primers using serial dilutions of universally unmethylated DNAs (EpiScope® Unmethylated HCT116 DKO gDNA; TaKaRa, Tokyo, Japan). The normalized methylation value (NMV) was defined as follows: NMV = (TRGs-S/TRGs-FM)/(ACTB-S/ACTB-FM), where TRGs-S and TRGs-FM represent TRG methylation levels in the sample and universally methylated DNAs, respectively. *ACTB*-S and *ACTB*-FM correspond to b-actin in the sample and universally methylated DNAs, respectively. To analyze the methylation status of *CDH13* \[[@B49-cancers-10-00027]\], *p16* \[[@B50-cancers-10-00027]\], *MGMT* \[[@B51-cancers-10-00027]\], *CDH1* \[[@B50-cancers-10-00027]\], *COL1A2* \[[@B52-cancers-10-00027]\], *RASSF1A* \[[@B50-cancers-10-00027]\], *DAPK* \[[@B51-cancers-10-00027]\], *CCBE1* \[[@B53-cancers-10-00027]\], *DCC* \[[@B54-cancers-10-00027]\], *SALL3* \[[@B48-cancers-10-00027]\], *GAL* \[[@B55-cancers-10-00027]\], *NPY* \[[@B56-cancers-10-00027]\], *HCRT* \[[@B56-cancers-10-00027]\], *TAC1* \[[@B57-cancers-10-00027]\], *SST* \[[@B58-cancers-10-00027]\], *GALR1* \[[@B47-cancers-10-00027]\], *GALR* \[[@B59-cancers-10-00027]\], *NPY1R* \[[@B56-cancers-10-00027]\], *NPY2R* \[[@B56-cancers-10-00027]\], *NPY4R* \[[@B56-cancers-10-00027]\], *NPY5R* \[[@B56-cancers-10-00027]\], *TACR1* \[[@B57-cancers-10-00027]\], *HCRTR1* \[[@B56-cancers-10-00027]\], *HCRTR2* \[[@B56-cancers-10-00027]\], *SSTR1* \[[@B58-cancers-10-00027]\], *NPFFR1* \[[@B56-cancers-10-00027]\], *NPFFR2* \[[@B56-cancers-10-00027]\], *VEGFR1* \[[@B60-cancers-10-00027]\], *VEGFR2* \[[@B60-cancers-10-00027]\], and *VEGFR3* \[[@B60-cancers-10-00027]\] primers, conditions and cutoff values were used as previously described. A list of the primer sequences from the Q-MSP analysis is shown in [Table S1](#app1-cancers-10-00027){ref-type="app"}. The HPV status was evaluated using the HPV Typing Set (Takara, Tokyo, Japan), a PCR primer set specifically designed to identify HPV genotypes -16, -18, -31, -33, -35, -52 and -58 in genomic DNA. The PCR HPV Typing Set method was performed according to the manufacturer's protocol.

4.3. Data Analysis and Statistics {#sec4dot3-cancers-10-00027}
---------------------------------

The Q-MSP results and patient characteristics were compared using Student's *t*-tests. The overall methylation value for individual samples was determined by calculating the methylation index (MI), which was then used to determine the overall methylation rate in the individual samples \[[@B59-cancers-10-00027]\]. The MI for each sample was defined as the ratio of the number of methylated genes to the number of total genes tested (i.e., 30).

For the frequency analysis in the contingency tables, the associations between variables and methylation status were analyzed statistically using the chi-square test. DFS was calculated from the date of the initial treatment to the date of diagnosis of locoregional recurrence or distant metastasis. The prognostic value of the methylation status was assessed by performing multivariate Cox proportional hazards analysis adjusted for age (≥70 years versus \<70 years), sex, alcohol intake, smoking status, and tumor stage (I and II versus III and IV). Differences with P \< 0.05 were considered significant. All statistical analyses were performed using StatMate IV (ATMS Co. Ltd., Tokyo, Japan).

4.4. Systematic Literature Review {#sec4dot4-cancers-10-00027}
---------------------------------

A systematic search in the PubMed database using the following terms: methylation AND survival AND hypopharyngeal cancer OR laryngeal cancer OR oral cavity cancers were performed in order to identify studies reporting genes in which the detection of hypermethylation on their promoter region showed a statistically significant association with their use as a biomarker for prognosis ([Table 3](#cancers-10-00027-t003){ref-type="table"}).

4.5. Collection of Publicly Available Data from TCGA {#sec4dot5-cancers-10-00027}
----------------------------------------------------

Aberrant DNA methylation data contained in TCGA (available in May 2017) were collected from the MethHC (<http://methhc.mbc.nctu.edu.tw/php/index.php>) and using the Infinium Human Methylation 450 platform (Illumina, Inc., San Diego, CA, USA) and are expressed as β-values \[[@B61-cancers-10-00027]\].

5. Conclusions {#sec5-cancers-10-00027}
==============

In conclusion, high throughput epigenetic screening studies suggest differences in the epigenetic profiles of HPV-related and HPV-negative HNSCC, with the former characterized by hypermethylated genes. Better molecular classification of the head and neck tumors is required to provide prognostic as well as mechanistic information to improve patient care. Future planned studies will include a more diverse patient population and a more comprehensive view of the patient backgrounds and environmental factors.

This study was funded by a Grant-in-Aid for Scientific Research (No. 16K11228, No. 16K20239, No. 17K11380, No. 17K16903 and No. 17K16904) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan. The authors would like to thank Yuko Mohri for her excellent technical support.

The following are available online at <http://www.mdpi.com/2072-6694/10/1/27/s1>. Figure S1: Methylation status of the 30 TRGs in HNSCC and normal samples in TCGA database. The methylation data for 30 TRGs in HNSCC and normal samples were collected from TCGA database. \* *p* \< 0.05. Table S1: Q-MSP Primer List.
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![Summary of hypermethylation of tumor-related gene (TRG) promoters in HNSCC samples. Shown here are the methylation frequencies (%) of 30 TRGs in the cohort. Grey bars: Fu: full panel; blue bars: Hy: hypopharyngeal cancer; orange bars: La: laryngeal cancer; green bars: Or: oral cavity cancer.](cancers-10-00027-g001){#cancers-10-00027-f001}

![Association between methylation indices (MI) and selected clinical parameters. The mean MI for the various groups was compared using Student\'s *t*-tests. Shown are the associations between MI and selected epidemiologic and clinical characteristics in (**A**) full panel; (**B**) hypopharyngeal cancer; (**C**) laryngeal cancer; and (**D**) oral cavity cancer. Statistical comparisons between the groups are represented as a mean with standard deviation. A probability of \<0.05 (\* *p* \< 0.05) was considered to represent a statistically significant difference.](cancers-10-00027-g002){#cancers-10-00027-f002}

![Odds ratios (ORs) for recurrence of cancers. Shown are the ORs of recurrence associated with methylation of different tumor-related genes (TRGs) in (**a**) hypopharyngeal cancer; (**b**) laryngeal cancer; and (**c**) oral cancer. ORs were calculated based on the Cox proportional hazards model, adjusted for age (≥70 years vs. \<70 years), sex, alcohol exposure, smoking status, and tumor stage (I and II vs. III and IV). CI: confidence interval. \* *p* \< 0.05.](cancers-10-00027-g003){#cancers-10-00027-f003}

cancers-10-00027-t001_Table 1

###### 

Clinicopathological data of head and neck squamous cell carcinoma (HNSCC) patients under study.

  --------------------------------------------------------------------------------------------
  Patient and Tumor Characteristics   Full Panel\   Hypopharynx\   Larynx\      Oral Cavity\
                                      (*n* = 178)   (*n* = 61)     (*n* = 49)   (*n* = 68)
  ----------------------------------- ------------- -------------- ------------ --------------
  *Age*                                                                         

  Mean ± S.D.                         65.8 ± 11.2   66.7 ± 10.2    68.9 ± 8.3   62.9 ± 13.1

  *Gender*                                                                      

  Male                                153 (86%)     54 (89%)       47 (96%)     52 (76%)

  Female                              25 (14%)      7 (11%)        2 (4%)       16 (24%)

  *Alcohol exposure*                                                            

  Ever                                135 (76%)     51 (84%)       40 (81%)     44 (65%)

  Never                               43 (24%)      10 (16%)       9 (18%)      24 (35%)

  *Smoking status*                                                              

  Smoker (\>1 pack/20 years)          124 (70%)     46 (75%)       35 (71%)     43 (63%)

  Smoker (\<1 pack/20 years)          9 (5%)        3 (5%)         2 (4%)       4 (6%)

  Non-smoker                          45 (25%)      12 (20%)       12 (25%)     21 (31%)

  *Tumor size*                                                                  

  T1                                  16 (9%)       1 (2%)         4 (8%)       11 (16%)

  T2                                  62 (35%)      21 (34%)       7 (14%)      34 (50%)

  T3                                  40 (22%)      19 (31%)       16 (33%)     5 (7%)

  T4                                  60 (34%)      20 (33%)       22 (45%)     18 (27%)

  *Lympho-node status*                                                          

  N0                                  81 (46%)      18 (30%)       24 (49%)     39 (57%)

  N+                                  97 (54%)      43 (70%)       25 (51%)     29 (43%)

  *Stage*                                                                       

  I                                   14 (8%)       0 (0%)         4 (8%)       10 (15%)

  II                                  32 (18%)      9 (14%)        3 (6%)       20 (29%)

  III                                 37 (21%)      16 (26%)       12 (24%)     9 (13%)

  IV                                  95 (53%)      36 (59%)       30 (61%)     29 (43%)

  *Recurrence events*                                                           

  Positive                            67 (38%)      25 (41%)       20 (41%)     22 (32%)

  Negative                            111 (62%)     36 (59%)       29 (59%)     46 (68%)
  --------------------------------------------------------------------------------------------

cancers-10-00027-t002_Table 2

###### 

Correlation between tumor sites and methylation status.

  Genes       Methylation Status   Hypopharynx (N = 61)   Larynx (N = 49)   Oral Cavity (N = 68)   *p*-Values ^χ^              
  ----------- -------------------- ---------------------- ----------------- ---------------------- ---------------- ---------- -----------------
  *CDH13*     Methylated           17                     14                19                                                 
              Unmethylated         44                     35                49                     0.935            0.94       0.993
  *p16*       Methylated           10                     11                32                                                 
              Unmethylated         51                     38                36                     0.422            0.006 \*   0.0002 \*
  *MGMT*      Methylated           16                     19                23                                                 
              Unmethylated         45                     30                45                     0.16             0.582      0.348
  *CDH1*      Methylated           20                     17                21                                                 
              Unmethylated         41                     32                47                     0.833            0.664      0.817
  *COL1A2*    Methylated           23                     20                21                                                 
              Unmethylated         38                     29                47                     0.74             0.267      0.414
  *RASSF1A*   Methylated           25                     14                25                                                 
              Unmethylated         36                     35                43                     0.176            0.354      0.623
  *DAPK*      Methylated           32                     24                26                                                 
              Unmethylated         29                     25                42                     0.717            0.246      0.105
  *CCBE1*     Methylated           34                     29                40                                                 
              Unmethylated         27                     20                28                     0.717            0.969      0.723
  *DCC*       Methylated           34                     31                44                                                 
              Unmethylated         27                     18                24                     0.425            0.873      0.298
  *SALL3*     Methylated           38                     33                41                                                 
              Unmethylated         23                     16                27                     0.582            0.435      0.813
  *GAL*       Methylated           5                      11                18                                                 
              Unmethylated         56                     38                50                     0.035 \*         0.619      0.007 \*
  *NPY*       Methylated           9                      12                26                                                 
              Unmethylated         52                     37                42                     0.197            0.117      0.003 \*
  *HCRT*      Methylated           39                     20                42                                                 
              Unmethylated         22                     29                26                     0.016 \*         0.025 \*   0.799
  *TAC1*      Methylated           38                     33                37                                                 
              Unmethylated         23                     16                31                     0.582            0.159      0.365
  *SST*       Methylated           50                     33                54                                                 
              Unmethylated         11                     16                14                     0.077            0.14       0.714
  *GALR1*     Methylated           31                     32                33                                                 
              Unmethylated         30                     17                35                     0.127            0.072      0.795
  *GALR2*     Methylated           14                     21                35                                                 
              Unmethylated         47                     28                33                     0.026 \*         0.357      *p* \< 0.001 \*
  *NPY1R*     Methylated           19                     14                24                                                 
              Unmethylated         42                     35                44                     0.769            0.444      0.618
  *NPY2R*     Methylated           24                     17                19                                                 
              Unmethylated         37                     32                49                     0.616            0.435      0.17
  *NPY4R*     Methylated           22                     18                27                                                 
              Unmethylated         39                     31                41                     0.942            0.744      0.671
  *NPY5R*     Methylated           20                     17                26                                                 
              Unmethylated         41                     32                42                     0.833            0.695      0.519
  *TACR1*     Methylated           27                     30                31                                                 
              Unmethylated         34                     19                37                     0.077            0.095      0.88
  *HCRTR1*    Methylated           35                     31                46                                                 
              Unmethylated         26                     18                22                     0.531            0.622      0.228
  *HCRTR2*    Methylated           46                     37                58                                                 
              Unmethylated         15                     12                10                     0.99             0.181      0.156
  *SSTR1*     Methylated           46                     35                49                                                 
              Unmethylated         15                     14                19                     0.638            0.94       0.666
  *NPFFR1*    Methylated           52                     37                50                                                 
              Unmethylated         9                      12                18                     0.197            0.809      0.102
  *NPFFR2*    Methylated           48                     36                54                                                 
              Unmethylated         13                     13                14                     0.522            0.452      0.92
  *VEGFR1*    Methylated           28                     17                26                                                 
              Unmethylated         33                     32                42                     0.235            0.695      0.378
  *VEGFR2*    Methylated           26                     16                26                                                 
              Unmethylated         35                     33                42                     0.285            0.535      0.612
  *VEGFR3*    Methylated           18                     15                26                                                 
              Unmethylated         43                     34                42                     0.9              0.394      0.297

Hy vs. La: Hypopharynx vs. Larynx; La vs. Or: Larynx vs. Oral cavity; Hy vs. Or: Hypopharynx vs. Oral cavity; ^χ^ Chi square test used to calculate *p*-value. \* *p* \< 0.05 considered statistically significant, the same as below.

cancers-10-00027-t003_Table 3

###### 

Published studies of TRG hypermethylation and survival of hypopharyngeal cancer, laryngeal cancer, and oral cavity cancer patients.

  Study (Reference.)                       Year   Country    Cases   Primary Site   Genes Studied                                                              Significant Association between Methylation and Survival \*
  ---------------------------------------- ------ ---------- ------- -------------- -------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------
  Wei DM \[[@B22-cancers-10-00027]\]       2015   China      53      hypopharyx     *DAPK*                                                                     Worse survival (*p* = 0.045)
  Stephen JK \[[@B23-cancers-10-00027]\]   2010   USA        79      larynx         *HIC1*, *ESR1*                                                             *HIC1* worse survival (*p* \< 0.01)
  Shen Z \[[@B24-cancers-10-00027]\]       2016   China      104     larynx         *miR-34a*                                                                  Worse survival (*p* = 0.023)
  Shen Z \[[@B25-cancers-10-00027]\]       2017   China      91      larynx         *Claudin-11*                                                               Worse survival (*p* = 0.007)
  Shen Z \[[@B26-cancers-10-00027]\]       2017   China      93      larynx         *SHISA3*                                                                   Worse survival (HR = 2.71; 95% CI: 1.024--7.177; *p* = 0.047)
  Ogi K \[[@B27-cancers-10-00027]\]        2002   Japan      96      oral cavity    *MINT31*, *MINT1*, *MINT2*, *MINT27*, *p16*, *p15*, *p14*, *DCC*, *DAPK*   *MINT31* worse survival (HR = 3.79; 95% CI: 1.58--9.10; *p* \< 0.001)
  Long NK \[[@B28-cancers-10-00027]\]      2008   Japan      40      oral cavity    *RECK*                                                                     Worse survival (*p* = 0.023)
  Taioli E \[[@B29-cancers-10-00027]\]     2009   USA        88      oral cavity    *MGMT*, *CDKN2A*, *RASSF1*                                                 *MGMT* worse survival (HR = 3.49, 95% CI: 1.62--7.52; *p* = 0.001)
  Supić G \[[@B30-cancers-10-00027]\]      2009   Serbia     77      oral cavity    *CDH1*, *DAPK*, *MGMT*, *WRN*, *APC*                                       *CDH1* worse survival (*p* = 0.024)
  Huang KH \[[@B31-cancers-10-00027]\]     2009   Taiwan     166     oral cavity    *RASSF1A*, *HIN-1*, *RASSF2A*, *PTEN*                                      *RASSF1A* worse survival (n = 166; HR = 2.09, 95% CI: 1.25--3.50), *HIN-1* worse survival (n = 116; HR = 2.66; 95% CI: 1.30--5.45)
  Supic G \[[@B32-cancers-10-00027]\]      2011   Serbia     47      oral cavity    *DAPK*, *p16*, *RASSF1A*, *APC*, *CDH1*, *RUNX3*, *WIF1*, *MGMT*, *hMLH*   *DAPK* worse survival (HR = 4.11, 95% CI: 1.46--1.56; *p* = 0.007)
  Dong Y \[[@B33-cancers-10-00027]\]       2012   China      30      oral cavity    *p16*                                                                      *p16* worse survival (*p* = 0.021)
  Lin HY \[[@B34-cancers-10-00027]\]       2013   Taiwan     44      oral cavity    *DAPK*, *RASSF1A*, *IRF8*, *SFRP1*                                         *DAPK* worse survival (HR = 2.83, 95% CI: 1.05--7.63; *p* = 0.042)
  Yang CM \[[@B35-cancers-10-00027]\]      2016   Taiwan     86      oral cavity    *SOX21-AS1*                                                                *SOX21-AS1* worse survival (*p* = 0.002)
  Ribeiro IP \[[@B36-cancers-10-00027]\]   2016   Portugal   93      oral cavity    *GATA5*, *WT1*, *MSH6*, *PAX5*                                             *GATA5* worse survival (*p* = 0.049)
